HAVCR2 and glioblastoma: The second study by Mohme and colleagues [17] also found no significant difference in percentage of TIM-3 positivity on peripheral CD4+ and CD8+ T cells comparing healthy donors, patients with newly diagnosed primary glioblastoma and recurrent glioblastoma.